In Vitro Phosphate Binding Capacity of a Dietary Supplement for Dogs and Cats


Dietary supplement
phosphate binder
renal disorder

How to Cite

Bruni, N. ., Martello, E., Adami, R. ., Meineri, G., Perondi, F., Costale, A., Rosso, E. ., & Lippi, I. (2022). In Vitro Phosphate Binding Capacity of a Dietary Supplement for Dogs and Cats. Journal of Pharmacy and Nutrition Sciences, 12, 86–91.


Hyperphosphatemia has been recognized as a serious and frequent complication in dogs and cats with Chronic Kidney Disease (CKD). The veterinary approach is mainly based on reducing phosphorus in the diet and with phosphate (P) binders. In this in vitro study we compared seven supplements with a different combination of ingredients for dogs and cats at pH 3 and 7 to estimate the P binding capacity overtime. Our results confirmed the best binding capacity of supplements at acid compared to basic condition. The P binding capacity of two products containing mainly calcium carbonate, calcium lactate-gluconate and chitosan was higher compared to the other tested at the same conditions.


Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, et al. ISFM Consensus guidelines on the diagnosis and management of feline chronic kidney disease. J Feline Med Surg 2016; 18(3): 219-39.

Bernachon N, Fournel S, Gatto H, Monginoux P, McGahie D. Effect of a product containing the dietary phosphate binders calcium and magnesium carbonate associated with other reno-protectant substances (Pronefra®) on blood parameters and mineral balance in adult cats. Intern J Appl Res Vet Med. 2014; 12.

Martello E, Perondi F, Bruni N, Bisanzio D, Meineri G, Lippi I. Chronic kidney disease and dietary supplementation: effects on inflammation and oxidative stress. Vet Sci 2021; 8(11).

Biasibetti E, Martello E, Bigliati M, Biasato I, Cocca T, Bruni N, et al. A long term feed supplementation based on phosphate binders in feline chronic kidney disease. Veterinary Research Communications 2018; 42(2): 161-7.

Martello E, Perondi F, Capucchio MT, Biasato I, Biasibetti E, Cocca T, et al. Efficacy of a new dietary supplement in dogs with advanced chronic kidney disease. Peer J 2020; 8: e9663.

Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney international Supplement 2004; (90): S25-32.

Wagner E, Schwendenwein I, Zentek J. Effects of a dietary chitosan and calcium supplement on Ca and P metabolism in cats. Berliner und Munchener tierarztliche Wochenschrift 2004; 117(7-8): 310-5.

Fritz K, Taylor K, Parmar M. Calcium Carbonate. 2022 Aug 1. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing 2022. PMID: 32965974.

Yaguchi A, Akahane K, Tsuchioka K, Yonekubo S, Yamamoto S, Tamai Y, et al. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study. BMC Nephrol 2019; 20(1): 465.

Segev G, Bandt C, Francey T, Cowgill LD. Aluminum toxicity following administration of aluminum-based phosphate binders in 2 dogs with renal failure. J Vet Intern Med 2008; 22(6): 1432-5.

Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83(1): 66-73.

King EJ. The colorimetric determination of phosphorus. Biochem J 1932; 26(2): 292-7.

Polzin DJ. Chronic kidney disease in small animals. Vet Clin North Am Small Anim Pract 2011; 41(1): 15-30.

Peitsch T, Matthes M, Brandenburg V, Epple M. An in vitro crystallization setup to assess the efficiency of different phosphate binders in nephrology: quantitative analytical considerations. Analytical Methods 2010; 2(7): 901-11.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2022 Natascia Bruni, Elisa Martello, Raffaella Adami, Giorgia Meineri, Francesca Perondi, Annalisa Costale, Elena Rosso, Ilaria Lippi